Previous studies have reported that ITGA2 is closely related to chemotherapy sensitivity and that its high expression mediates gemcitabine resistance in pancreatic cancer [13], 5-FU resistance in colorectal cancer [22], and 5-FU and ADR resistance in gastric cancer [23]. Here, ITGA2 is linked to familial pancreatic carcinoma.